GIQuIC Registry Announces New Partnership with Health Catalyst

The GI Quality Improvement Consortium, Inc. (GIQuIC), a joint collaboration of the American College of Gastroenterology (ACG) and American Society of Gastrointestinal Endoscopy (ASGE) offering the only national gastroenterology-focused clinical registry, will be moving to a powerful new technology platform powered by Health Catalyst, Inc. (“Health Catalyst”, Nasdaq: HCAT). A leading provider of data and analytics technology and services to healthcare organizations, Health Catalyst acquired ARMUS Corporation in 2022, which allows GIQuIC to take advantage of ARMUS’s HYBRID Clinical Registry and Reporting solution.

ARMUS by Health Catalyst’s HYBRID cloud-based registry platform is currently utilized by more than three dozen clinical registries. Health Catalyst’s extensive experience with data extraction allows a streamlined user experience and enhances GIQuIC’s data capture process. With its patient-centric approach, HYBRID positions its customers well for longitudinal data collection and robust reporting to fuel quality improvement as well as reporting to CMS’ Quality Payment Program.

“This collaboration will enhance the service we already provide to our registry participants by allowing GIQuIC to leverage the depth and breadth of offerings and prior experience and success Health Catalyst has with respect to registry services and healthcare analytics. The ultimate goal is to empower our users to improve the quality of the healthcare they provide to their patients,” explained Costas H. Kefalas, MD, MMM, FACG, FASGE, President of the GIQuIC Board of Directors. “This experience will be especially valuable as we enhance the registry functionality, add additional endoscopy procedures and digestive disease states, and facilitate patient-reported outcomes.”

Working in tandem, GIQuIC and Health Catalyst plan to transition existing registry operations for colonoscopy and esophagogastroduodenoscopy (EGD) procedures by the beginning of 2024 with the goal of adding additional data collection and reporting relative to endoscopic procedures and disease states, to include inflammatory bowel disease (IBD), endoscopic retrograde cholangiopancreatography (ERCP), endoscopic bariatric therapy (EBT), endoscopic ultrasound (EUS), wireless capsule endoscopy and deep enteroscopy in the near future.

“Data abstraction and registry reporting are critical functions of healthcare organizations, and we are delighted GIQuIC has selected Health Catalyst to power this important work,” said Dan Burton, CEO of Health Catalyst. “We look forward to an enduring partnership with the GIQuIC team and registry participants.”

About GIQuIC

The GI Quality Improvement Consortium, Ltd. (GIQuIC) is a clinical medical registry established by gastroenterologists in 2010. A joint collaboration of the American College

of Gastroenterology (ACG) and the American Society for Gastrointestinal Endoscopy (ASGE), GIQuIC improves patient outcomes by allowing participating physicians to benchmark quality, identify gaps in care, and develop specific and targeted quality improvement initiatives. The registry also contributes data to advance GI research and to assist the GI societies in developing guidelines for patient care. Visit www.giquic.org for more information.

About Health Catalyst

Health Catalyst is a leading provider of data and analytics technology and services to healthcare organizations committed to being the catalyst for massive, measurable, data-informed healthcare improvement. Its customers leverage the cloud-based data platform—powered by data from more than 100 million patient records and encompassing trillions of facts—as well as its analytics software and professional services expertise to make data-informed decisions and realize measurable clinical, financial, and operational improvements. Health Catalyst envisions a future in which all healthcare decisions are data informed. Visit www.healthcatalyst.com for more information.

About Gastrointestinal Endoscopy
Gastrointestinal endoscopic procedures allow the gastroenterologist to visually inspect the upper gastrointestinal tract (esophagus, stomach and duodenum) and the lower bowel (colon and rectum) through an endoscope, a thin, flexible device with a lighted end and a powerful lens system. Endoscopy has been a major advance in the treatment of gastrointestinal diseases. For example, the use of endoscopes allows the detection of ulcers, cancers, polyps and sites of internal bleeding. Through endoscopy, tissue samples (biopsies) may be obtained, areas of blockage can be opened and active bleeding can be stopped. Polyps in the colon can be removed, which has been shown to prevent colon cancer.

About the American Society for Gastrointestinal Endoscopy
Since its founding in 1941, the American Society for Gastrointestinal Endoscopy (ASGE) has been dedicated to advancing patient care and digestive health by promoting excellence and innovation in gastrointestinal endoscopy. ASGE, with almost 16,000 members worldwide, promotes the highest standards for endoscopic training and practice, fosters endoscopic research, recognizes distinguished contributions to endoscopy, and is the foremost resource for endoscopic education. Visit Asge.org and ValueOfColonoscopy.org for more information and to find a qualified doctor in your area.

 

American Society for Gastrointestinal Endoscopy
3300 Woodcreek Drive Downers Grove, IL 60515
P (630) 573-0600
F (630) 963-8332

Media Contact

Andrea Lee
Director of Marketing and Communications
630.570.5603
ALee@asge.org